Elite Pharmaceuticals, Inc. (ELTP) Free cash flow 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$22.8MFY2026 · since FY2017: -$9.0M → $22.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $22.8M | +291.4% |
| FY2025 | $5.8M | +244.2% |
| FY2024 | -$4.0M | -68.7% |
| FY2023 | -$2.4M | -139.9% |
| FY2022 | $6.0M | +109.8% |
| FY2021 | $2.9M | +256.6% |
| FY2020 | -$1.8M | +73.2% |
| FY2019 | -$6.8M | -36.5% |
| FY2018 | -$5.0M | +44.4% |
| FY2017 | -$9.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →